title: Phenytoin prodrug: preclinical and clinical studies.
abstract: The currently available phenytoin (PHT) solution has many disadvantages stemming from poor aqueous solubility of PHT. A novel approach to solve the problem has been the synthesis of a phosphate ester of PHT (PHT prodrug ACC-9653). This water-soluble compound is metabolized rapidly into PO4 and PHT. A four center open-label, baseline-controlled study of 43 patients with epilepsy maintained on oral twice-daily PHT monotherapy was performed to evaluate the safety and pharmacokinetic profile of the prodrug. Patients received an i.v. or i.m. dose of ACC-9653 at a dose equivalent to the patients' morning dose of PHT. Intravenous dosages were infused at a rate of 75 mg/min, and i.m. dosages were given as one or two injections. After a period of 6 days, during which patients were again maintained with oral PHT, they were given a dose of ACC-9653 via whichever route they had not yet received. The Tmax of the prodrug averaged 5.7 and 36 min (0.095 and 0.606 h) after i.v. and i.m. administrations, respectively. The elimination half-life of ACC-9653 (conversion from prodrug to PHT) after i.v. and i.m. administration was 8.4 and 32.7 min (0.140 and 0.545 h), respectively, and both were independent of the dose. The plasma clearance of ACC-9653 was not dependent on dose or route of administration and averaged 19.8 +/- 1.16 and 17.8 +/- 0.83 L/h after i.v. and i.m. administrations, respectively. The area under curve ratio of PHT after i.m. and i.v. ACC-9653 was 1.17 +/- 0.13 which was not significantly different from 1.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Neurology, University of Minnesota, Minneapolis.
authors.forename: I E
authors.initials: IE
authors.lastname: Leppik
authors.forename: R
authors.initials: R
authors.lastname: Boucher
authors.forename: B J
authors.initials: BJ
authors.lastname: Wilder
authors.forename: V S
authors.initials: VS
authors.lastname: Murthy
authors.forename: C A
authors.initials: CA
authors.lastname: Rask
authors.forename: C
authors.initials: C
authors.lastname: Watridge
authors.forename: N M
authors.initials: NM
authors.lastname: Graves
authors.forename: R J
authors.initials: RJ
authors.lastname: Rangel
authors.forename: P
authors.initials: P
authors.lastname: Turlapaty
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D010919:Placebos; D011355:Prodrugs / Q000493:pharmacokinetics*; D011897:Random Allocation
chemical_list: D010919:Placebos; D011355:Prodrugs; D010672:Phenytoin; C043114:fosphenytoin